Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

Inclusion Criteria: * Patients must have been previously diagnosed with histologically or cytologically confirmed symptomatic multiple myeloma, which requires the presence of all three of the following International Myeloma Working Group criteria, except as noted: * Clonal bone marrow plasma cells \>= 10% * A monoclonal protein in either serum or urine * Evidence of end-organ damage that can be attributed to the underlying plasma cell proliferative disorder (to include one of the following): * Hypercalcemia (corrected calcium \> 2.75 mmol/L or 11.5 mg/dL) * Renal insufficiency attributable to myeloma (serum creatinine \> 1.9 mg/dL) * Anemia; normochromic, normocytic with a hemoglobin value \>= 2 g/dL below the lower limit of normal, or a hemoglobin or \< 10 g/dL * Bone lytic lesions, severe osteopenia, or pathologic fractures * Patients with a biopsy-proven plasmacytoma and either a serum or urine monoclonal protein will also be considered to have met the diagnostic criteria for multiple myeloma in the absence of clonal marrow plasmacytosis of \>= 10% * Patients must have measurable disease, as defined by at least one of the following: * Serum monoclonal protein level \>= 0.5 g/dL for immunoglobulin (Ig)G, IgA, or IgM disease * Monoclonal protein or total serum IgD \>= 0.5 g/dL for IgD disease * Urinary M-protein excretion of \>= 200 mg over a 24-hour period * Involved free light chain level \>= 10 mg/dL, along with an abnormal free light…